OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

M. Thomas,M. Garassino,E. Felip,H. Sakai,X. Le,R. Veillon,E. Smit,J. Mazieres,A. Cortot,J. Raskin,S. Viteri,J.C.-H. Yang,M.-J. Ahn,Y.-L. Wu,R. Ma,J. Zhao,A. O'Brate,K. Berghoff,R. Bruns,G. Otto

Journal of Thoracic Oncology（2022）

引用 9|浏览10

暂无评分

摘要

Tepotinib is an oral, once daily, highly selective, potent MET inhibitor approved for MET exon 14 (METex14) skipping NSCLC based mainly on Cohort A of the multi-cohort Phase II VISION study. We report primary analysis (>9-months’ follow-up) of the independent confirmatory Cohort C; data cut-off February 20, 2022.

查看译文

关键词

nsclc,metex14,met exon,vision

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要